To further validate our conclusions, we used the ESTIMATE algorithm to assess the immune microenvironment of anti-PD1-treated patients and found that the expression of PSPH and SHMT1/2 was negatively correlated with patient immune scores (Fig. 7G to I), while PSAT1, PSPH, and SHMT2 were positively correlated with tumor purity (Fig. 7J to L). This evidence concerns the gene PSPH and neoplasm.